T32GM007223). K.R.M is an NSF Graduate Research Fellow. S.P. is supported by CT Stem Cell grant 14-SCA-YALE-05. P.R. is supported by an American Skin Association Research Scholar Award, was a New York Stem Cell Foundation-Druckenmiller Fellow, and was supported by CT Stem Cell grant 13-SCA-YALE- 20 To address these issues, we developed a genetically encoded biosensor (9) for measuring free NAD + concentrations within subcellular compartments. This sensor comprises a circularly permuted Venus fluorescent protein (cpVenus) and a bipartite NAD + -binding domain modeled from bacterial DNA ligase (Fig. 1A and fig. S1 ) that exclusively uses NAD + as a substrate (10) . Point mutations were introduced to prevent NAD + consumption and allow monitoring of NAD + within the predicted physiological range. Purified sensor and cpVenus ( fig. S2 ) had major excitation peaks at~500 nm that fluoresced at 520 nm (Fig. 1B) . NAD + decreased sensor fluorescence (excitation at 488 nm) in a dosedependent manner and minimally affected cpVenus fluorescence (Fig. 1 , B and C). A second excitation peak at 405 nm was unaffected by NAD + binding ( Fig. 1C and fig. S3 ), allowing ratiometric (488 nm/405 nm) measurements for normalizing sensor expression levels ( fig. S4 ). In vitro, the apparent NAD + dissociation constant (K d ) of the sensor was~65 mM (Fig. 1D ). Absorbance measurements revealed two major species at~415 and~488 nm that appeared to interconvert upon NAD + addition around ã 450-nm isosbestic point ( fig. S5 ). This indicates that the NAD + -bound species loses its fluorescence at 488 nm, converting to a species that absorbs at 415 nm but is nonfluorescent. Accordingly, NAD + did not affect the fluorescence lifetime after 488-nm excitation ( fig. S6 ), providing further evidence that fluorescence after 488-nm excitation solely represents the unbound fraction.
To confirm the reversibility of NAD + binding, we showed that elution of NAD + from the sensor returned fluorescence to that of a control sample (Fig. 1E) . We also monitored fluorescence in real time in the presence of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which has a higher affinity for NAD + than the sensor does and thereby competes for free NAD + in the absence of substrate. We observed a rapid recovery of fluorescence upon GAPDH addition (Fig. 1F) .
To determine sensor specificity, we evaluated fluorescence in the presence of related nucleotides and NAD + precursors (Fig. 1G ). Only NAD + appreciably decreased sensor fluorescence. The absolute fluorescence intensities of the sensor and cpVenus displayed similar sensitivities to pH, and the NAD + -dependent responses of the sensor were minimally affected from pH 6.5 to 8.0 ( fig. S7) . Thus, pH effects can be accounted for by normalizing to cpVenus. Fluorescence intensity was slightly affected by temperature, but the K d of the unbound pool was not appreciably affected between 20°and 37°C ( fig. S8) .
Localization sequences directing the sensor to the nucleus, cytoplasm, and mitochondria ( Fig. 2A) S11 ). NAD + decreased fluorescence of the cytoplasmic sensor in a dose-dependent manner (apparent K d ,~300 mM; dynamic range, 30 mM to 1 mM) (Fig. 2B and fig. S12 ) and minimally affected cpVenus. The mean of the fluorescence ratio (488 nm/405 nm) for the cytoplasmic sensor in nonpermeabilized HEK293T cells relative to that of cpVenus was interpolated to reveal a free NAD + value of 106 mM [95% confidence interval (CI), 92 to 122 mM]. Using the same strategy, we determined that the concentration of free NAD + was 109 mM in the nucleus (95% CI, 87 to 136 mM) ( fig. S13 ) and 230 mM in mitochondria (95% CI, 191 to 275 mM). Mitochondrial measurements were fit to the curve obtained with the cytoplasmic sensor. We confirmed the cytoplasmic calculations with live microscopy, using adherent human cervical cancer HeLa cells permeabilized with saponin and equilibrated with varying external NAD + concentrations (Fig. 2C) . mitochondrial SIRT3 is around 250 mM (1), supporting the idea that these enzymes are poised to be regulated by local NAD + fluctuations. The similarity in nuclear and cytoplasmic NAD + levels suggests that NAD + is readily exchangeable between the nucleus and cytoplasm.
Mammalian cells predominantly rely on the NAMPT-dependent salvage pathway for NAD + biosynthesis (4), so presumably NAD + concentrations in all subcellular compartments would be affected by NAMPT inhibition. To test this idea, cells were treated with FK866 {N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide}, an NAMPT inhibitor, and NAD + concentrations in various compartments were monitored with live flow cytometry (Fig. 3A) or microscopy ( fig. S15 ). In the absence of FK866, NAD + concentrations remained constant ( fig. S16 ). The rate of free NAD + depletion was similar in the nucleus and cytoplasm (half-life,~2 hours) and largely depended on PARP activity, as demonstrated by treatment with the inhibitor Tiq-A [thieno(2,3-c)isoquinolin-5-one] (fig. S16 ). Depletion of mitochondrial free NAD + occurred at a slower rate (half-life,~8 hours) and was minimally affected by Tiq-A. FK866 treatment for 16 hours significantly decreased free NAD + by more than 85% in all compartments-nuclear (8 mM; 95% CI, 6 to 11 mM), cytoplasmic (3 mM; 95% CI, 0.1 to 6 mM), and mitochondria (32 mM; 95% CI, 27 to 38 mM); this decrease was not prevented by Tiq-A treatment ( fig. S16 ).
We confirmed our pharmacological studies with NAMPT by using small interfering RNAs (siRNAs), which depleted free NAD + in all compartments ( fig. S17) increased free NAD + to 83 mM (95% CI, 72 to 98 mM) through a parallel pathway that bypasses NAMPT (11) (Fig. 3B and fig. S18 ). NR itself was not recognized by the sensor (Fig.  1G ) and did not alter sensor fluorescence ( fig.  S19 ). The levels of free NAD + correlated with PARP activity, induced by H 2 O 2 genotoxic stress (Fig. 3C) .
A heretofore unanswered question is how pools of NAD + in the nucleus, cytoplasm, and mitochondria are established and maintained. To address the specific roles of NMNAT isoforms in the creation and maintenance of compartmentalized NAD + pools, we used validated siRNAs ( fig. S20 ) to systematically deplete the NMNAT enzymes that catalyze the final step of NAD + biosynthesis in each of these subcellular compartments ( fig. S21) (5) . Depletion of NMNAT2 decreased cytoplasmic NAD + to 58 mM (95% CI, 50 to 67 mM), consistent with its subcellular expression pattern. Nuclear NAD + concentrations, however, were not significantly affected ( fig. S22 ), indicating that NMNAT1 is sufficient to meet the nuclear NAD + demand but cannot fully compensate for depletion of NAD + in the cytoplasm. This finding is consistent with the lethality of individual knockout animal models (12, 13) . Depletion of NMNAT1 did not significantly change nucleocytoplasmic NAD + concentrations, but levels were lower ( fig. S23A ). We wondered whether the relatively similar amounts of NMNAT1 and NMNAT2 in HEK293T cells masked the NMNAT1 contribution to the cytoplasmic compartment, so we examined HeLa cells, which express relatively less NMNAT2 (fig. S24) . In HeLa cells, depleting NMNAT1 significantly decreased cytoplasmic NAD + to 38 mM (95% CI, 32 to 44 mM) ( fig. S23B ). Together, these data demonstrate that NMNAT1 can contribute to the cytoplasmic NAD + pool and highlight cell type-dependent differences in NAD + regulation.
Our data indicate that free NAD + in mitochondria fluctuates distinctly from that in the nucleocytoplasm (Fig. 3A and fig. S25 ). The mitochondrial NMNAT isoform, NMNAT3, is thought to generate mitochondrial NAD + ; consistent with this idea, depleting NMNAT3 in HEK293T cells significantly decreased mitochondrial NAD + concentrations to 103 mM (95% CI, 88 to 123 mM) (Fig. 4A and fig. S26 ). Depleting NMNAT2 also decreased mitochondrial NAD + concentrations ( Fig. 4A and fig. S26 ). This suggests that NAD + produced in the cytoplasm can influence mitochondrial stores and that NMN is not the sole source of mitochondrial NAD + . Supporting this idea, NMNAT3 depletion in HeLa cells, which contain low amounts of this enzyme, did not affect mitochondrial NAD + concentrations ( fig. S27 ). In contrast, NMNAT2 depletion both decreased cytoplasmic NAD + to 38 mM (95% CI, 33 to 45 mM) and decreased mitochondrial NAD + to 134 mM (95% CI, 113 to 161 mM) (Fig. 4B and fig. S28 ). Addition of NR did not restore mitochondrial NAD + concentrations, implying that cytoplasmic NAD + , and not NMN, maintains mitochondrial NAD + in HeLa cells (Fig. 4B) . Thus, there appear to be at least two mechanisms for maintaining mitochondrial NAD Representative images are shown on the left (scale bar, 25 mm). Fluorescence intensities were normalized to scramble RNA (siScramble) and mitochondrial cpVenus (cpV) controls. Plotted are means ± SEM (n = 3) from REML analysis. **P < 0.01.
